Kinetics of immune responses to nasal challenge with meningococcal polysaccharide one year after serogroup-C glycoconjugate vaccination

Clinical Infectious Diseases

Volumn 52, Issue 11, 2011, Pages 1317-1323

  Wing, James B ^a   Smart, Lynne ^a   Borrow, Ray ^b   Findlow, Jamie ^b   Findlow, Helen ^b   Heath, Andrew W ^a   Read, Robert C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOCONJUGATE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE; POLYSACCHARIDE;

ADULT; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COLONIZATION; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; SALIVA ANALYSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MENINGOCOCCAL VACCINES; NASAL MUCOSA; NEISSERIA MENINGITIDIS, SEROGROUP C; POLYSACCHARIDES, BACTERIAL; PROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 79957465017     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir198     Document Type: Article

References (29)

1. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: A success story. Vaccine 2001; 20(Suppl 1):S58-67. (Pubitemid 32925012)
2. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-7. (Pubitemid 38970013)
3. Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: Contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006; 55:887-96. (Pubitemid 43974695)
4. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: Lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8:851-61.
5. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: Database analysis. BMJ 2003; 326:365-6. (Pubitemid 36241472)
6. Auckland C, Gray S, Borrow R, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 2006; 194:1745-52. (Pubitemid 44902007)
7. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of correlates of protection. Infect Immun 2001; 69:1568-73. (Pubitemid 32187610)
8. Maslanka SE, Gheesling LL, Libutti DE, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 1997; 4:156-67. (Pubitemid 27130227)
9. Lal G, Balmer P, Joseph H, Dawson M, Borrow R. Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin Diagn Lab Immunol 2004; 11:272-9. (Pubitemid 38380806)
10. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969; 129:1307-26.
11. Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 2001; 8:616-23. (Pubitemid 32428891)
12. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003; 10:780-6. (Pubitemid 37129487)
13. Trotter CL, Borrow R, Findlow J, et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol 2008; 15:1694-8.
14. Southern J, Borrow R, Andrews N, et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol 2009; 16:194-9.
15. Snape MD, Kelly DF, Salt P, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: Persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 2006; 43:1387-94. (Pubitemid 44845637)
16. Edwards EA, Devine LF, Sengbusch GH, Ward HW. Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. Scand J Infect Dis 1977; 9:105-10. (Pubitemid 8103945)
17. Gilmore A, Jones G, Barker M, Soltanpoor N, Stuart JM. Meningococcal disease at the University of Southampton: Outbreak investigation. Epidemiol Infect 1999; 123:185-92. (Pubitemid 29509314)
18. Neal KR, Nguyen-van-Tam JS, Slack RC, Kaczmarski EB, White A, Ala'Aldeen DA. Seven-week interval between acquisition of a meningococcus and the onset of invasive disease. A case report. Epidemiol Infect 1999; 123:507-9. (Pubitemid 30076934)
19. Uhr JW, Moller G. Regulatory effect of antibody on the immune response. Adv Immunol 1968; 8:81-127.
20. Heyman B. Antibody feedback suppression: Towards a unifying concept? Immunol Lett 1999; 68:41-5. (Pubitemid 29265650)
21. Getahun A, Heyman B. Studies on the mechanism by which antigenspecific IgG suppresses primary antibody responses: Evidence for epitope masking and decreased localization of antigen in the spleen. Scand J Immunol 2009; 70:277-87.
22. Nurkka A, MacLennan J, Jantti V, Obaro S, Greenwood B, Kayhty H. Salivary antibody response to vaccination with meningococcal A/C polysaccharide vaccine in previously vaccinated and unvaccinated Gambian children. Vaccine 2000; 19:547-56.
23. Borrow R, Fox AJ, Cartwright K, Begg NT, Jones DM. Salivary antibodies following parenteral immunization of infants with a meningococcal serogroup A and C conjugated vaccine. Epidemiol Infect 1999; 123:201-8. (Pubitemid 29509316)
24. Zhang Q, Choo S, Everard J, Jennings R, Finn A. Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents. Infect Immun 2000; 68:2692-7. (Pubitemid 30253843)
25. Robinson K, Neal KR, Howard C, et al. Characterization of humoral and cellular immune responses elicited by meningococcal carriage. Infect Immun 2002; 70:1301-9. (Pubitemid 34163405)
26. Maiden MC, Ibarz-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737-43. (Pubitemid 351364476)
27. Foster RA, Carlring J, Lees A, et al. Functional T-cell deficiency in adolescents who experience serogroup C meningococcal disease despite receiving the meningococcal serogroup C conjugate vaccine. Clin Vaccine Immunol 2010; 17:1104-10.
28. Foster RA, Carlring J, McKendrick MW, et al. Evidence of a functional B-cell immunodeficiency in adults who experience serogroup C meningococcal disease. Clin Vaccine Immunol 2009; 16:692-8.
29. Evans CM, Pratt CB, Matheson M, et al. Nasopharyngeal colonization by Neisseria lactamica and induction of protective immunity against Neisseria meningitidis. Clin Infect Dis 2011; 52:70-7.